These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 3493816

  • 1. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
    Donaldson VH, Wagner CJ, Tsuei B, Kindness G, Bing DH, Harrison RA, Rosen FS.
    Blood; 1987 Apr; 69(4):1096-101. PubMed ID: 3493816
    [Abstract] [Full Text] [Related]

  • 2. Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies.
    Donaldson VH, Harrison RA, Rosen FS, Bing DH, Kindness G, Canar J, Wagner CJ, Awad S.
    J Clin Invest; 1985 Jan; 75(1):124-32. PubMed ID: 3965500
    [Abstract] [Full Text] [Related]

  • 3. Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema.
    Cugno M, Nuijens J, Hack E, Eerenberg A, Frangi D, Agostoni A, Cicardi M.
    J Clin Invest; 1990 Apr; 85(4):1215-20. PubMed ID: 2318974
    [Abstract] [Full Text] [Related]

  • 4. Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema.
    Jackson J, Sim RB, Whaley K, Feighery C.
    J Clin Invest; 1989 Feb; 83(2):698-707. PubMed ID: 2536404
    [Abstract] [Full Text] [Related]

  • 5. A rapid method for functional determination of C1 esterase inhibitor in plasma.
    Cullmann W, Kövary PM, Dick W, Czarnetzki B, Echternach-Happle K.
    Clin Chim Acta; 1982 Mar 12; 119(3):237-42. PubMed ID: 6175450
    [Abstract] [Full Text] [Related]

  • 6. C1-inhibitor--biochemical properties and clinical applications.
    Al-Abdullah IH, Greally J.
    Crit Rev Immunol; 1985 Mar 12; 5(4):317-30. PubMed ID: 3899511
    [Abstract] [Full Text] [Related]

  • 7. Hereditary and acquired deficiencies of C1 inhibitor.
    Davis AE.
    Immunodefic Rev; 1989 Mar 12; 1(3):207-26. PubMed ID: 2698641
    [Abstract] [Full Text] [Related]

  • 8. C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: Implication for a role in hereditary angioedema.
    Madsen DE, Sidelmann JJ, Biltoft D, Gram J, Hansen S.
    Biochim Biophys Acta; 2015 Jun 12; 1850(6):1336-42. PubMed ID: 25800206
    [Abstract] [Full Text] [Related]

  • 9. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.
    Joseph K, Tholanikunnel BG, Bygum A, Ghebrehiwet B, Kaplan AP.
    J Allergy Clin Immunol; 2013 Aug 12; 132(2):470-5. PubMed ID: 23672780
    [Abstract] [Full Text] [Related]

  • 10. Interactions of C1(-)-inhibitors from normal persons and patients with type II hereditary angioneurotic edema with purified activated Hageman factor (factor XIIa).
    Donaldson VH, Mitchell BH, Everson B, Ratnoff OD.
    Blood; 1990 Feb 15; 75(4):911-21. PubMed ID: 2302459
    [Abstract] [Full Text] [Related]

  • 11. Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema.
    Kramer J, Katz Y, Rosen FS, Davis AE, Strunk RC.
    J Clin Invest; 1991 May 15; 87(5):1614-20. PubMed ID: 1902490
    [Abstract] [Full Text] [Related]

  • 12. Remissions induced in hereditary angioneurotic edema with an attenuated androgen (danazol): correlation between concentrations of C1-inhibitor and the forth and second components of complement.
    Pitts JS, Donaldson VH, Forristal J, Wyatt RJ.
    J Lab Clin Med; 1978 Oct 15; 92(4):501-7. PubMed ID: 712189
    [Abstract] [Full Text] [Related]

  • 13. Interaction of human plasma kallikrein and its light chain with C1 inhibitor.
    van der Graaf F, Koedam JA, Griffin JH, Bouma BN.
    Biochemistry; 1983 Sep 27; 22(20):4860-6. PubMed ID: 6556071
    [Abstract] [Full Text] [Related]

  • 14. In vitro interaction of C1-inhibitor with thrombin.
    Cugno M, Bos I, Lubbers Y, Hack CE, Agostoni A.
    Blood Coagul Fibrinolysis; 2001 Jun 27; 12(4):253-60. PubMed ID: 11460008
    [Abstract] [Full Text] [Related]

  • 15. Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases.
    Woo P, Lachmann PJ, Harrison RA, Amos N, Cooper C, Rosen FS.
    Clin Exp Immunol; 1985 Jul 27; 61(1):1-8. PubMed ID: 4042415
    [Abstract] [Full Text] [Related]

  • 16. Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s.
    Prandini MH, Reboul A, Colomb MG.
    Biochem J; 1986 Jul 01; 237(1):93-8. PubMed ID: 3099750
    [Abstract] [Full Text] [Related]

  • 17. Fluid-phase interaction of C1 inhibitor (C1 Inh) and the subcomponents C1r and C1s of the first component of complement, C1.
    Chesne S, Villiers CL, Arlaud GJ, Lacroix MB, Colomb MG.
    Biochem J; 1982 Jan 01; 201(1):61-70. PubMed ID: 6282262
    [Abstract] [Full Text] [Related]

  • 18. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
    Kaplan AP, Joseph K.
    Adv Immunol; 2014 Jan 01; 121():41-89. PubMed ID: 24388213
    [Abstract] [Full Text] [Related]

  • 19. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.
    Schapira M, Scott CF, Colman RW.
    J Clin Invest; 1982 Feb 01; 69(2):462-8. PubMed ID: 6173399
    [Abstract] [Full Text] [Related]

  • 20. [New preparation method of C1 esterase for the dosage of its plasma inhibitor].
    Gozin D, Ollier-Hartmann MP, Lerable J, Hartmann L, Soulier JP.
    Biomed Pharmacother; 1983 Feb 01; 37(5):228-30. PubMed ID: 6607074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.